Biophysics of neurodegenerative disease

CMIC Group, the first and largest CRO in Japan with extended services in drug development and GMP manufacturing in the US, Japan and Asia, held a webinar Advanced ODT Technologies for Drug Development in Japan and the US on April 11, 2019.Since its introduction in the 1980s, the market of orally disintegrating tablet (ODT) has grown annually and ODTs are now available in a variety of therapeutic areas, both over-the-counter (OTC) and by prescription. ODT market is projected to reach US$21B in 2023.In this webinar, CMIC and Aprecia experts talked about advanced ODT technologies and its advantages in drug development.

Clinical trial data can be remarkably (and unnecessarily) difficult to read. Companies spin, short-sellers hawk, and everyone else is left swimming through the muck. But there is an art to reading scientific results — and you can learn it.

This presentation will summarize the state-of-the-art in transporters in drug development based on four recent ITC3 whitepapers (Clin Pharmacol Ther 104, October 2018). Practical overview of emerging transporters of clinical relevance will be provided (e.g., OCT1, OATP2B1, etc.). Best practice in design of clinical DDI studies will be illustrated with recent advances in the study of OCT1, P-gp, and BCRP. Considerations for optimal selection of clinical probe drugs, including future potential utility of transporter biomarkers, also will be discussed.

The voyage of a cell or gene therapy from initial hypothesis to commercial delivery is complex and challenging. It requires a broad spectrum of scientific expertise, innovative technologies, and optimized processes to ensure these advanced therapeutics make it to market. In this GEN webinar, our panelists—two industry leaders—will discuss what it takes to develop a cell or gene therapy from concept to commercialization, alongside a conversation about innovations that are likely to shape the future of advanced therapy discovery and biomanufacturing.